In the News: October Regulatory and Development Updates
Camargo
NOVEMBER 11, 2020
announced a collaboration to develop a companion diagnostic for Vitrakvi® (larotrectinib) NTRK (neurotrophic tropomyosin receptor kinase) inhibitor, approved in the U.S. In October, less than 18 months later, the FDA approved the companion test, which will allow physicians to better identify target eligible patients. Ken Phelps.
242 
Let's personalize your content